Concepedia

Tomomi Nakayama Iwata

TN

Statistics

Publications

2

Citations

313

H-Index

2

Active since

2018

Affiliations

Daiichi-Sankyo (Japan)(Current)

Tomomi Nakayama Iwata is an author at Daiichi-Sankyo (Japan) specializing in her2-positive breast cancer immunotherapy, antibody-drug conjugate therapy, and cancer immunology.

Publications per year

2018–2019

2

Publications

2

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida et al. · Molecular Cancer Therapeutics · 2018 · 273 citations

, , +17

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model

Tomomi Nakayama Iwata, Kiyoshi Sugihara, Teiji Wada et al. · PLoS ONE · 2019 · 40 citations · Full text

, , +17

1–2 of 2